清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

P25. Characteristics, treatment options, and predictors of clinical failure among Pseudomonas aeruginosa infection with microbiologically confirmed intermediate or resistant carbapenem susceptibility profile: a multicenter clinical experience on behalf of CASPER (CArbapenem-reSistant Pseudomonas aERuginosa during and after the COVID-19 pandemic) study group

碳青霉烯 铜绿假单胞菌 医学 重症监护医学 多中心研究 微生物学 内科学 抗生素 生物 细菌 随机对照试验 遗传学
作者
Andrea Dessilani,Shaniko Kaleci,Gabriella Orlando,Maurizio Del Monte,Andrea Bedini,Erica Franceschini,Maria Cristina Albertini,L Benassi,Alessandra Oliva,Sergio Mezzadri,M Codeluppi,Lucia Serio,Emanuela Biagioni,Gabriele Melegari,Claudia Venturelli,Mario Sarti,Lesley De Pietri,Massimo Girardis,Cristina Mussini,Marianna Meschiari
出处
期刊:JAC-antimicrobial resistance [Oxford University Press]
卷期号:7 (Supplement_2)
标识
DOI:10.1093/jacamr/dlaf046.025
摘要

Abstract Background This study aims to assess the risk factors for clinical failure in carbapenem-intermediate-resistant Pseudomonas aeruginosa (CiRPA) infections, focusing on susceptibility profiles, prior treatments, and the effectiveness of current targeted antibiotic regimens. Methods We conducted a multicenter, retrospective cohort study of adults with microbiologically confirmed CiRPA infections (any sites) admitted to four large tertiary care university hospital between January 2018 to December 2024. Three comparison groups were defined: i) intermediate meropenem (MEM) minimum inhibitory concentration (MIC, 4-8 μg/ml) vs. resistant (>8 μg/ml); ii) active monotherapy vs. active combination therapy; iii) ceftolozane/tazobactam (C/T) vs. the best available therapy (BAT) among a subgroup of patients with pneumonia or bloodstream infection (BSI). The primary outcome was clinical success, a composite one defined as defined as survival at 30-days, resolution of signs and symptoms of infection at the end of therapy, and the absence of recurrent infection due to P. aeruginosa within 90-day. Results A total of 197 eligible patients were included: 99 (50%) pneumonia and 31 (16%) BSI. Intensive care unit (ICU) admission was required for 127 patients (65%), and 72 (36%) presented with sepsis or septic shock. C/T and ceftazidime-avibactam (CZA) were the most used antibiotics, accounting for 25% and 15% of treatments, respectively. No significant differences in clinical success were observed between patients with intermediate or resistant meropenem profiles (48.39% vs. 48.48%; p = 0.989) or between those treated with C/T comparing to the BAT (47.50% vs. 37.93%; p = 0.308), even with continuous infusion or bolus administration. In the multivariate analysis, prior use of anti-Pseudomonas cephalosporins and ventilator-associated were identified as significant predictors of clinical failure (OR 2.28, 95% CI 1.16-4.49, and 3.42, 95% CI 1.7-6.89, respectively). Conclusions No significant clinical success advantage was observed for the intermediate susceptibility profile, combination therapy, or C/T use in CRPA infections. Prior use of anti-Pseudomonas cephalosporins together with VAP infections resulted significant predictors of clinical failure including recurrent infection, highlighting the independent role of antimicrobial stewardship in improving clinical outcomes for patients with Pseudomonas aeruginosa infections. Larger studies are needed to confirm these findings and optimize therapeutic strategies for CRPA infections.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
包子完成签到 ,获得积分10
刚刚
Aman完成签到,获得积分10
3秒前
清脆的飞阳完成签到,获得积分10
4秒前
斯文败类的应助被躺平写文章采纳,获得10
21秒前
herpes完成签到 ,获得积分0
31秒前
32秒前
32秒前
Zhao完成签到 ,获得积分10
36秒前
欣欣完成签到,获得积分10
36秒前
39秒前
忧伤的傲芙完成签到,获得积分10
42秒前
小元元完成签到 ,获得积分10
43秒前
微笑的巧蕊完成签到 ,获得积分10
46秒前
躺平写文章完成签到,获得积分10
50秒前
专注湘完成签到,获得积分10
50秒前
Cosmosurfer完成签到,获得积分0
1分钟前
眯眯眼的安雁完成签到 ,获得积分10
1分钟前
害羞雪珊完成签到,获得积分10
1分钟前
温柔樱桃完成签到 ,获得积分10
1分钟前
满意的伊完成签到,获得积分10
1分钟前
魔幻的松思完成签到,获得积分10
1分钟前
飞哥与小佛完成签到,获得积分10
1分钟前
1分钟前
Julian完成签到,获得积分0
1分钟前
从容美女发布了新的文献求助10
1分钟前
seeyou14发布了新的文献求助20
1分钟前
健忘初露完成签到,获得积分10
1分钟前
YANGMJ完成签到,获得积分10
1分钟前
汉堡包的应助被科研通管家采纳,获得50
1分钟前
n01W97的应助被科研通管家采纳,获得20
1分钟前
Orange的应助被科研通管家采纳,获得10
1分钟前
yhr完成签到,获得积分10
2分钟前
闪闪的访烟完成签到,获得积分10
2分钟前
yiyi完成签到 ,获得积分10
2分钟前
aRuuuu完成签到 ,获得积分10
2分钟前
兴奋雅香完成签到,获得积分10
2分钟前
小马甲的应助被amiee采纳,获得10
3分钟前
开放的乐驹完成签到 ,获得积分10
3分钟前
俊秀的箴完成签到,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185483
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834498
捐赠科研通 7783085
什么是DOI,文献DOI怎么找? 3434576
关于科研通互助平台的介绍 2558929
邀请新用户注册赠送积分活动 2481346